Description
Retatrutide + Cagrilintide Technical Overview
Retatrutide and Cagrilintide are synthetic peptide compounds investigated for their interactions with distinct metabolic and endocrine receptor systems.
Retatrutide, also known as LY3437943, is a chemically modified peptide developed as a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).
Its activity across three receptor systems distinguishes it from peptides that selectively activate one or two metabolic hormone receptors.
Cagrilintide, also known as AM833, is a long-acting, lipidated analogue of the pancreatic hormone amylin. Its molecular structure has been modified to support prolonged pharmacological activity compared with native amylin.
Amylin receptor signaling participates in physiological processes involving gastrointestinal function, food-intake regulation, and metabolic homeostasis.
Retatrutide and Cagrilintide therefore represent distinct pharmacological approaches to investigating peptide-mediated endocrine signaling.
Retatrutide has been studied in experimental and clinical research examining metabolic regulation and the effects of simultaneous GLP-1, GIP, and glucagon receptor activation.
Cagrilintide has been independently investigated in studies involving amylin receptor signaling and metabolic responses.
The combination of these compounds presents additional questions concerning receptor interactions, physicochemical compatibility, and formulation stability.
The pharmacological properties of either compound alone cannot be assumed to describe the behavior of a combined preparation.
Compound Information
| Property | Retatrutide | Cagrilintide |
|---|---|---|
| Compound Name | Retatrutide | Cagrilintide |
| Alternative Names | LY3437943 | AM833 |
| CAS Number | 2381089-83-2 | 1415456-99-3 |
| Chemical Classification | Modified synthetic peptide | Lipidated amylin analogue |
| Primary Receptor Targets | GLP-1R, GIPR, GCGR | Amylin receptor complexes |
| Research Category | Metabolic and endocrine research | Amylin signaling research |
| Listed Quantity | 5mg | 10mg |
Retatrutide Molecular Specifications
| Property | Value |
|---|---|
| Compound Name | Retatrutide |
| Alternative Name | LY3437943 |
| CAS Number | 2381089-83-2 |
| Peptide Classification | Triple receptor agonist |
| Receptor Targets | GLP-1R, GIPR, GCGR |
| Structural Characteristics | Chemically modified, lipidated peptide |
| Source | Synthetic |
Cagrilintide Molecular Specifications
| Property | Value |
|---|---|
| Compound Name | Cagrilintide |
| Alternative Name | AM833 |
| CAS Number | 1415456-99-3 |
| PubChem CID | 171397054 |
| Molecular Formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| Molecular Weight | Approximately 4409 g/mol |
| Peptide Classification | Long-acting amylin analogue |
| Structural Characteristics | Lipidated peptide with intramolecular disulfide bonding |
| Source | Synthetic |
The molecular formula and molecular weight of Cagrilintide refer to its registered chemical structure.
The CAS numbers identify the individual compounds and do not describe the combined formulation as a separate chemical entity.
The listed quantities do not establish whether the compounds are supplied together in one vial or as separate preparations.
Chemical References:
Chemical identifiers and Cagrilintide molecular specifications are supported by PubChem records. PubChem
Storage and Handling
- Store the research material according to manufacturer-provided stability documentation.
- Protect the compounds from excessive moisture, direct light, and unnecessary temperature fluctuations.
- Keep containers securely sealed under the recommended laboratory storage conditions.
- Follow handling procedures appropriate for the verified physical form and chemical composition.
- Do not assume that the stability characteristics of individual compounds apply to their combined formulation.
- Consult formulation-specific analytical documentation when evaluating compatibility and stability.
Lyophilized Format
Retatrutide and Cagrilintide may be supplied for laboratory research in lyophilized (freeze-dried) form.
Lyophilization removes water from peptide preparations and can support compound stability when appropriate storage conditions are maintained.
The stability of individual peptides depends on their molecular structure, formulation, packaging, and environmental conditions.
For research preparations containing multiple peptides, additional considerations include chemical compatibility, aggregation, and formulation-dependent degradation.
The physical form and stability of a Retatrutide–Cagrilintide preparation should be verified through manufacturer documentation and formulation-specific analytical testing.
Research Use Disclaimer
Retatrutide and Cagrilintide are investigational compounds that are not FDA-approved for human therapeutic use.
The combined formulation has not been established as safe or effective for human administration.
This material is described exclusively for laboratory research purposes.
It is not intended for human or veterinary consumption, clinical use, diagnostic applications, or therapeutic administration.
Research-use labeling does not independently establish compliance with applicable FDA regulations.
RETATRUTIDE + CAGRILINTIDE RESEARCH
Retatrutide and Cagrilintide have been investigated independently in pharmaceutical research programs examining metabolic and endocrine signaling pathways.
Retatrutide is characterized by its activity at GLP-1, GIP, and glucagon receptors.
Cagrilintide is a long-acting amylin analogue that interacts with receptor systems distinct from those activated by Retatrutide.
These compounds are therefore relevant to scientific investigations comparing incretin, glucagon, and amylin signaling.
A randomized phase 2 clinical trial published in The New England Journal of Medicine in 2023 investigated Retatrutide in adults with obesity.
Cagrilintide was independently evaluated in a randomized phase 2 clinical trial published in The Lancet in 2021.
These studies provide evidence concerning the individual compounds.
They do not establish the pharmacological behavior, safety, stability, or effectiveness of a combined Retatrutide–Cagrilintide formulation.
Triple Receptor Signaling Research
Retatrutide is investigated as an agonist of three G protein-coupled receptors involved in endocrine regulation.
The GLP-1 receptor, GIP receptor, and glucagon receptor participate in distinct but interconnected metabolic signaling pathways.
Experimental research has examined the pharmacological activity of Retatrutide across these receptor systems.
Simultaneous receptor activation provides a model for investigating interactions between incretin and glucagon signaling.
Published studies have contributed to understanding the compound’s receptor pharmacology and endocrine responses.
GLP-1 and GIP Receptor Research
GLP-1 and GIP are endogenous incretin hormones involved in glucose-dependent insulin secretion and metabolic regulation.
Their receptors participate in intracellular signaling pathways associated with pancreatic endocrine function.
Retatrutide has been developed to activate both receptor systems alongside the glucagon receptor.
Scientific investigations have examined the effects of this combined receptor activity in experimental and clinical settings.
These findings contribute to research into the relationship between incretin signaling and broader metabolic regulation.
Glucagon Receptor Research
The glucagon receptor participates in signaling pathways associated with hepatic glucose metabolism and energy regulation.
Retatrutide includes glucagon receptor agonism as part of its triple receptor pharmacology.
Researchers have investigated how glucagon receptor activation interacts with GLP-1 and GIP receptor signaling.
These studies contribute to understanding the pharmacological characteristics of multi-receptor peptide agonists.
Amylin Receptor Research
Cagrilintide is a synthetic, long-acting analogue of the pancreatic hormone amylin.
Amylin is involved in physiological processes related to gastrointestinal function, food-intake signaling, and metabolic homeostasis.
Amylin receptor complexes are formed through interactions between the calcitonin receptor and receptor activity-modifying proteins.
Cagrilintide has been investigated in experimental and clinical pharmacology research examining these receptor systems.
Its molecular modifications distinguish it from native amylin and contribute to its prolonged pharmacological activity.
Metabolic Signaling Research
Retatrutide and Cagrilintide interact with distinct hormonal receptor systems.
Retatrutide research involves GLP-1, GIP, and glucagon receptor signaling.
Cagrilintide research focuses on amylin receptor pharmacology.
These different receptor profiles provide a scientific basis for comparative investigations into endocrine signaling mechanisms.
However, pharmacological interactions arising from simultaneous exposure to both compounds require direct experimental evaluation.
Receptor Interaction Research
Research involving multiple peptide compounds requires consideration of receptor selectivity, downstream signaling, and potential pharmacological interactions.
Retatrutide activates three metabolic hormone receptors, while Cagrilintide interacts with amylin receptor complexes.
The individual receptor profiles of these compounds have been characterized in published research.
Specific interactions between Retatrutide and Cagrilintide cannot be established by combining results from separate clinical studies.
Formulation Compatibility Research
Combined peptide formulations introduce additional physicochemical considerations.
Relevant areas of investigation include peptide stability, aggregation, adsorption, and formulation-dependent degradation.
The stability of Retatrutide alone does not establish its stability when combined with Cagrilintide.
Likewise, stability data obtained from individual Cagrilintide preparations cannot automatically be applied to a mixture containing Retatrutide.
Analytical testing of the specific formulation is necessary to evaluate its chemical composition and stability.
Research Applications
| Research Area | Laboratory Research Focus |
|---|---|
| GLP-1 Receptor Research | GLP-1R signaling mechanisms |
| GIP Receptor Research | GIPR-mediated endocrine signaling |
| Glucagon Receptor Research | GCGR activation and downstream pathways |
| Amylin Receptor Research | Amylin receptor pharmacology |
| Metabolic Signaling | Comparison of endocrine signaling systems |
| Receptor Pharmacology | Characterization of receptor activation |
| Peptide Stability | Physicochemical stability assessment |
| Formulation Research | Compatibility and analytical characterization |
FREQUENTLY ASKED QUESTIONS
What Is Retatrutide 5mg + Cagrilintide 10mg?
Retatrutide 5mg + Cagrilintide 10mg is a research product listing two synthetic peptide compounds with distinct receptor targets.
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors.
Cagrilintide is a long-acting amylin analogue investigated in metabolic and endocrine research.
Both compounds have been studied independently.
What Are the CAS Numbers of Retatrutide and Cagrilintide?
Retatrutide has CAS number 2381089-83-2.
Cagrilintide has CAS number 1415456-99-3.
These identifiers refer to the individual chemical compounds rather than their combination.
What Is the Molecular Weight of Cagrilintide?
Cagrilintide has a molecular weight of approximately 4409 g/mol.
Its molecular formula is C₁₉₄H₃₁₂N₅₄O₅₉S₂, based on the registered chemical structure.
What Is the Difference Between Retatrutide and Cagrilintide?
Retatrutide activates GLP-1, GIP, and glucagon receptors.
Cagrilintide is a long-acting amylin analogue that interacts with amylin receptor complexes.
Their distinct receptor profiles make them relevant to different areas of endocrine and metabolic research.
Has the Retatrutide and Cagrilintide Combination Been Clinically Studied?
Published clinical trials have evaluated Retatrutide and Cagrilintide independently.
As of October 2026, no published clinical trial was identified that directly establishes the safety or efficacy of their combined use.
How Should Retatrutide and Cagrilintide Be Stored?
Storage conditions should follow the manufacturer’s verified stability documentation.
For combined preparations, individual compound stability data may not accurately predict the stability of the mixture.
What Research Areas Involve These Compounds?
Retatrutide and Cagrilintide have been investigated in research involving incretin signaling, glucagon receptor activity, amylin receptor pharmacology, endocrine regulation, and metabolic pathways.
Their specific combined pharmacology requires further investigation.
Are Retatrutide and Cagrilintide FDA-Approved?
Neither Retatrutide nor Cagrilintide is FDA-approved in the United States.
The combined formulation is not an FDA-approved medication and has not been established as safe or effective for human use.
SCIENTIFIC REFERENCES
1. Jastreboff A.M. et al. (2023)
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
New England Journal of Medicine, 389, 514–526.
This randomized phase 2 trial investigated Retatrutide in adults with obesity and examined metabolic and body-weight-related outcomes.
https://pubmed.ncbi.nlm.nih.gov/37366315/
2. Rosenstock J. et al. (2023)
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA.
The Lancet, 402, 529–544.
This study investigated Retatrutide-associated endocrine and metabolic outcomes in participants with type 2 diabetes.
https://pubmed.ncbi.nlm.nih.gov/37385280/
3. Lau D.C.W. et al. (2021)
Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity: A Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial.
The Lancet, 398, 2160–2172.
This clinical study investigated the long-acting amylin analogue Cagrilintide.
https://doi.org/10.1016/S0140-6736(21)01751-7
Research Evidence Note: These studies examine Retatrutide and Cagrilintide independently. They do not establish the safety, efficacy, stability, or pharmacological properties of the Retatrutide 5mg + Cagrilintide 10mg combination.
CERTIFICATE OF ANALYSIS (COA)
A Certificate of Analysis (COA) provides analytical information about research compounds, including their identity, purity, and measured chemical characteristics.
For products containing Retatrutide and Cagrilintide, analytical documentation should identify both compounds and verify their respective quantities.
Depending on the procedures performed, testing documentation may include results from high-performance liquid chromatography (HPLC) and mass spectrometry (MS).
For combined preparations, additional testing may be necessary to assess formulation compatibility and stability.
Certificates for individual peptide batches do not automatically establish the characteristics of a combined formulation.
For information about available analytical documentation, contact:
Peptide Lives
Website: https://peptidelives.com
Reviews
There are no reviews yet.